Mining services company Thiess has settled a class action by fly-in fly-out workers who alleged they were not paid for time spent on the bus travelling home from a Pilbara-based liquefied natural gas processing plant owned by Woodside Energy.
Nine has won more time to file its evidence in advance of a six-week trial in defamation proceedings by surgeon Dr Munjed Al Muderis, despite a judge noting its “under-resourcing” of the matter, which the court heard could involve the broadcaster calling up to 40 witnesses.
Sydney law firm Baybridge Lawyers has lost a bid to block a rival firm that’s located in the same office building from registering its ‘LawBridge’ trade mark.
Star Entertainment can add new claims to a dispute over renovations at its Sydney casino, despite the fact that the defendant builder may be time barred from deflecting liability onto a subcontractor.
Eleven current and former Star Entertainment executives have refuted ASIC’s claims that they breached their duties in relation to the casino operator’s lax money laundering compliance, with all but two denying they had a duty to ensure the company complied with its legal obligations.
Prime Minister Anthony Albanese has derided former Attorney-General Christian Porter for reportedly leading Clive Palmer’s $300 billion arbitration claim against the federal government.
Justice Paul Brereton has been appointed to lead the new National Anti-Corruption Commission, with the CEO of AUSTRAC, the Disability Discrimination Commissioner, as well as two senior figures at NSW ICAC also tapped for senior roles.
The corporate watchdog has commenced a probe into ASX’s handling of the CHESS replacement program, including in relation to possible continuous disclosure breaches and misleading or deceptive conduct.
Port operations provider Engage Marine is seeking to obtain copies of restricted documents in the ACCC’s case against TasPorts, as it mounts its own competition suit against the Tasmanian government-owned body.
Beauty giant McPherson’s has denied ASIC’s claims that it misled the market and breached its disclosure obligations in 2020, arguing that a document showing sales of its Dr LeWinn’s line were down by $21 million was a draft that couldn’t have been used to revise a financial forecast.